Outpatient Surgery Magazine

Running on Empty - August 2019 - Subscribe to Outpatient Surgery Magazine

Outpatient Surgery Magazine, providing current information on Surgical Services, Surgical Facility Administration, Outpatient Surgery News and Trends, OR Excellence and more.

Issue link: http://outpatientsurgery.uberflip.com/i/1153553

Contents of this Issue

Navigation

Page 92 of 116

A U G U S T 2 0 1 9 • O U T PA T I E N T S U R G E R Y. N E T • 9 3 All cataract surgeons would like to use intracameral antibiotics to fight post-operative infection after cataract surgery. Two recently approved products could poten- tially eliminate the compliance issues associated with the compli- cated steroid eye drop regimen following cataract surgery. • Dexycu (dexamethasone intraocular suspension) 9%, the first FDA-approved intraocular steroid for the treatment of post-op inflammation, is a great example of how we can reduce the drop burden for a patient. This is a steroid that's injected through a single shot into the posterior chamber at the end of cataract surgery. The sustained-release drug dissolves over the course of a month. • Dextenza (dexamethasone ophthalmic insert 0.4 mg) is FDA- approved to treat both post-operative inflammation and pain. It is an intracanalicular insert that is placed in the lower punctum following cataract surgery. It is designed to deliver a steroid to the ocular sur- face for 30 days following insertion. EyePoint Pharmaceuticals Dexycu dexycu.com Ocular Therapeutix Dextenza dextenza.com • EYES WIDE OPEN Dr. Bailey views a video on administration of Dexycu (dexamethasone intraocular suspension) 9%, an intraocular steroid for the treatment of post-op inflammation.

Articles in this issue

Links on this page

Archives of this issue

view archives of Outpatient Surgery Magazine - Running on Empty - August 2019 - Subscribe to Outpatient Surgery Magazine